Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **dpy-19-like 3 pseudogene** (ENSG00000270333), also referred to as **E3 ubiquitin-protein ligase XIAP pseudogene** or **XIAPP1**, is a genomic DNA sequence classified as a pseudogene, meaning it is a non-functional remnant of a gene that has lost its protein-coding ability or is otherwise inactivated[^1^]. In this case, XIAPP1 resembles the gene for the **E3 ubiquitin-protein ligase XIAP (X-linked inhibitor of apoptosis protein)**, but it does not produce a functional protein. Pseudogenes may occasionally have regulatory functions but do not serve as direct drug targets, lack biological activity, and are not considered therapeutic targets in the sense used in pharmacology or drug development[1][5].\n\n[^1^]: [1][5]\n\nAdditional context: \n- ENSG00000270333 is explicitly annotated as a pseudogene in genomic resources, and there is no evidence it encodes an active protein product or functions as a molecular target.\n- The functional gene, **XIAP (BIRC4)**, is a different gene entirely and is an inhibitor of apoptosis protein, but it is not the pseudogene in question[1][4][5].\n- The presence of “E3 ubiquitin-protein ligase XIAP pseudogene, XIAPP1” as an alias highlights the homology, but also the lack of function, reinforcing that **this is not a drug target** and should not be confused with XIAP itself.\n\nSummary of errors: \n- The “dpy-19-like 3 pseudogene”/XIAPP1 is **not a target**; listing it as one is incorrect.\n\n--- \n\nIf you need information about the **functional XIAP protein (X-linked inhibitor of apoptosis protein / BIRC4)**, which is a validated drug target, refer specifically to those gene/protein entries instead[1][4][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on dpy-19-like 3 pseudogene (XIAPP1).